WATCHMAN Device Cuts Bleeding Risk by 45%
Boston Scientific announced on March 28, 2026, that its WATCHMAN FLX heart implant successfully met all endpoints in the pivotal CHAMPION-AF clinical trial, establishing it as a strong competitor to traditional blood thinners. The study, published in The New England Journal of Medicine, compared the device against non-vitamin K antagonist oral anticoagulants (NOACs) as a first-line therapy for stroke risk reduction in 3,000 patients with non-valvular atrial fibrillation.
The trial's primary safety results showed the WATCHMAN FLX device was statistically superior in preventing bleeding. Over 36 months, patients with the device had a non-procedural bleeding rate of 10.9% versus 19.0% for those on NOACs, representing a 45% relative risk reduction. For the primary efficacy goal—a composite of stroke, cardiovascular death, or systemic embolism—the device achieved statistical non-inferiority to NOACs, with event rates of 5.7% and 4.8%, respectively.
Trial Success Could Expand Market to 20 Million Patients
The positive trial data is a significant commercial catalyst for Boston Scientific, potentially quadrupling the addressable market for its WATCHMAN franchise to 20 million patients worldwide. Historically used for patients with contraindications to blood thinners, the CHAMPION-AF results could elevate the device to a first-line treatment option for a much broader patient population. This provides a major potential tailwind for the company's stock (BSX), which had declined 26% year-to-date following a weaker-than-expected sales forecast for 2026.
While the company guided for 10-11% revenue growth in 2026, down from 20% in 2025, the successful trial could reverse investor sentiment and unlock a multi-year growth trajectory for the WATCHMAN product line. Wall Street analysts remain largely optimistic, with a consensus price target on BSX suggesting over 50% upside from current levels, partly in anticipation of this expanded market access.
Skeptics Point to Higher 3.2% Ischemic Stroke Rate
Despite the overall positive outcome, some clinicians urge caution, pointing to nuances in the data. Critics note that while the device met its non-inferiority target for the main efficacy endpoint, the trial data showed a numerically higher rate of ischemic strokes in the WATCHMAN arm (3.2%) compared to the NOAC group (2.2%). Questions were also raised about the trial's design, including its industry funding and a wide non-inferiority margin that some argue made it easier to achieve the primary endpoint.
This debate suggests that while the WATCHMAN FLX is now a confirmed alternative, it is not a universal replacement for anticoagulants. The decision will likely involve a trade-off, with patients and doctors weighing the device's significant reduction in bleeding risk against the upfront procedural risks and the slight numerical difference in ischemic stroke rates. As one expert noted, the outcome solidifies the need for shared decision-making between patients and their cardiologists.
